Effects Safety of Integrative Therapy Combined with Tranrterial Chemoembolization Therapy for Patients with Liver Metastasis Colorectal Cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-11001682

Enrollment

Unknown

Registered

2011-01-06

Start date

2005-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Metastasis Colorectal Cancer

Interventions

1:TACE

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with Liver Metastasis Colorectal Cancer who are willing to receive Tranrterial Chemoembolization Therapy.

Exclusion criteria

Exclusion criteria: Servere liver renal dysfunction; allergic to anti-cancer drug or contrast agent; survival time less than 3 months.

Design outcomes

Primary

Measure	Time frame
overall survival (OS);	—

Countries

China

Contacts

Public ContactZHOU BO

bonheurzhou@hotmail.com+86 13621604953

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026